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Due to the complex nomenclature used in various regulations and guidance 
documents, the understanding of radiopharmaceutical precursor’s definition might 
be challenging. Depending on the context it could be interpreted as the substance 
which becomes a radiopharmaceutical after radiolabeling with a radionuclide of 
choice or a radionuclide which is used for radiolabeling of that substance. In this 
Chapter we present and discuss the requirements for precursors which are used in 
the preparation of theranostic radiopharmaceuticals, in particular for preparation 
of new radiopharmaceuticals for clinical trials within the EU. In discussion on the 
available methods for assessing the quality of radiopharmaceutical precursors and 
on the specified limits the reference to Ph. Eur. is made. Since the EANM guidelines 
for in-house preparation of radiopharmaceuticals also specify the need for testing 
the quality of radiopharmaceutical precursors, information provided herein might 
help the radiopharmacist working on the development of new theranostic agents 
to adequately define identity, strength, quality, purity and stability of the final 
radiopharmaceutical preparation.
Keywords: radiopharmaceutical precursors, radionuclide precursor,  
chemical precursor, peptides, IMPD, clinical trials
1. Introduction
This chapter deals with regulatory considerations related to radiopharmaceutical 
precursors within Europe. Outside, different aspects may apply, with the exception 
of certain harmonized documents. Radiopharmaceuticals are considered a safe 
class of medicinal products. Due to the small chemical quantities administered they 
are not expected to exhibit any measurable pharmacological effect [1]. However, 
since they are radioactive, the rules for minimizing the risk associated with the 
use of ionizing radiation to the patients and to the personnel must be observed. 
Depending on the chemical and physical properties, radiopharmaceuticals are 
used in major clinical areas for diagnostics and/or therapy [2]. As defined by the 
European Pharmacopeia (Ph. Eur.) general monograph (0125) radiopharmaceutical 
preparations or radiopharmaceuticals are medicinal products which, when ready 
for use, contain one or more radionuclides (radioactive isotopes) included for a 
medicinal purpose [3]. Importantly, they can also have the form of kits for radio-
pharmaceutical preparation, radionuclide generators and radionuclide precursors. 
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For the latter it is understood that they are not used in patients as such but only 
after attaching them to the suitable pharmaceutical vector. Although according 
to Ph. Eur. monograph (0125) radionuclide precursor is any radionuclide produced 
for radiolabeling of another substance prior to administration, and according to 
Ph. Eur. general monograph (2902) the substance, which is used as such vector, is 
defined as a chemical precursor for radiopharmaceutical preparations [4], the term 
radiopharmaceutical precursor is used interchangeably for either of the two above 
defined precursors (Figure 1).
2. Current regulatory framework
Given the complex nomenclature used in various regulations and guidance 
documents, the understanding of radiopharmaceutical precursor’s definition might 
be challenging. Depending on the context it could be interpreted as the substance 
which becomes a radiopharmaceutical after radiolabeling with a radionuclide 
of choice or a radionuclide which is used for radiolabeling of that substance. 
Therefore, the quality requirements and test methods specifications of precursors 
for use in preparation of theranostic radiopharmaceuticals can be discussed only in 
the light of current regulatory framework.
The preparation and use of radiopharmaceuticals are regulated by number of 
directives, regulations and rules. These documents may be classified with respect to 
the status of radiopharmaceutical preparation:
1. radiopharmaceuticals with marketing authorization (MA), regulated by:
• Directives: 2001/83/EC [5], 2003/94/EC [6], 2004/27/EC [7];
• GMP guidelines and annexes [8];
2. radiopharmaceuticals to be used in clinical trials (CT), regulated by:
• Directives: 2001/20/EC [9], 2003/94/EC [6], 2005/28/EC [10]
• and soon to be replaced by Regulation EU No 536/2014 [11];
3. unlicensed radiopharmaceuticals extemporaneously (just before use) 
 prepared, not for CT [12, 13].
Figure 1. 
Radiopharmaceutical precursors according to Ph. Eur.
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Radiopharmaceuticals with marketing authorization (MA) meet the 
requirements of GMP Annex 3 (Manufacture of Radiopharmaceuticals) [8] 
and EMA Guideline on Radiopharmaceuticals [12]. For the small scale prepara-
tion of radiopharmaceuticals outside the marketing authorization the guide 
of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection 
Co-operation Scheme (PIC/S) [14], the Guidelines on Good Radiopharmacy 
Practice (CRPP) issued by the Radiopharmacy Committee of European Association 
of Nuclear Medicine (EANM) [13] and the Chapter 5.19. Extemporaneous prepara-
tion of radiopharmaceutical preparations of the Ph. Eur. [15] are setting standards 
for good practices.
The translation of new radiopharmaceuticals from the preclinical stage into clin-
ical trials requires appropriate quality assessment essential to ensure efficacy and 
safety of both drug substance and drug product [16, 17]. The specific regulatory 
framework for the use of radiopharmaceuticals in clinical trials has been established 
in Europe [9, 11, 18]. From the radiopharmaceutical development perspective, the 
essential step is the preparation of an Investigational Medicinal Product Dossier 
(IMPD). This document includes information related to the chemical and pharma-
ceutical quality of the drug substance and drug product, as well as non-clinical data 
related to pharmacology, pharmacokinetics, radiation dosimetry and toxicology 
[19]. IMPD contains two main sections related to the production and quality control 
of the radiopharmaceutical: the drug substance (the active pharmaceutical ingredi-
ent, or API) and the drug product.
An active pharmaceutical ingredient (API) is defined as any substance or mixture 
of substances intended to be used in the manufacture of a drug product. Such 
substances are intended to provide pharmacological activity or other direct effect in 
the diagnosis as well as treatment of disease or to affect the structure and function 
of the body. Radiopharmaceutical preparations are often formulated using pre-
defined radionuclide precursors and chemical precursors. If such a preparation does 
not need a purification step prior to its administration to the patient, both precur-
sors used in the synthesis are considered to be an API in the drug substance part of 
IMPD. This in particular applies to precursors for theranostic applications where a 
radiometal is used to radiolabel a vector targeting the receptor, e.g. peptide. On the 
other hand, chemical precursors used in the manufacture of radiopharmaceuticals, 
which are purified after the radiolabeling process, are defined as API starting mate-
rial (e.g. chemical precursors for most F-18 and C-11 PET radiopharmaceuticals).
The manufacture of APIs should be carried out following general GMP 
requirements. In a GMP-based system, all processes are defined, systematically 
reviewed, and shown to be capable of consistently providing medicinal products 
of the required quality and complying with their specifications [20]. Written and 
approved protocols specifying critical steps, acceptance criteria, must be in place. 
Process validation is a crucial part of GMP, meaning that all critical steps of manu-
facturing processes as well as significant changes to these processes are validated. 
It should be noted that the requirements for validations differ depending whether 
marketing authorization, clinical trials or in-house preparation of radiopharma-
ceuticals are planned (see also Figure 2.) [21]. The qualification and validation 
aspects related to the small-scale “in house” preparation of radiopharmaceuticals 
are covered in the EANM guidance [22].
In the process of IMPD preparation the prime challenge is to establish quality 
specifications for radiopharmaceutical precursors. They are supposed to comprise 
a set of tests that are necessary to confirm identity, purity and strength of the drug 
substance. Issues under consideration are the definition of release criteria, analytical 
procedures and especially their validation. Main references to address these issues are 
the European Pharmacopeia and guidance provided by the International Conference 
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on Harmonization (ICH). Ph. Eur. provides general requirements for quality control 
of radiopharmaceutical precursors, in addition, a number of monographs for indi-
vidual radiopharmaceuticals and chemical precursors are available in the Ph. Eur.
The use of analytical methods described in the pharmacopeia allows to reduce 
the work load related to analytical method validation. This does not mean that 
a pharmacopeia method may be implemented without any preliminary testing 
and verification. As a minimum, the most critical parameters should be veri-
fied, depending on the intended method. If no pharmacopeia monograph exists, 
analytical methods need to be fully validated. As stated by the general reference 
document issued by ICH the objective of validation of an analytical procedure is to 
demonstrate that it is suitable for its intended purpose [23]. To validate an analytical 
method, the following characteristics may be considered: specificity, accuracy, lin-
earity range, precision (repeatability and intermediate precision), limit of detection 
(LOD), limit of quantitation (LOQ ) and robustness. Recently, recommendations 
for the validation of analytical methods which are specific for radiopharmaceuticals 
has been published by EANM [24].
3. Chemical precursors for radiopharmaceutical preparations
Chemical precursors for radiopharmaceutical preparations, are non-radioactive 
substances obtained by chemical synthesis for combination with a radionuclide in 
contrast to precursors manufactured using substances of human or animal origin [4].
The quality specification for chemical precursors is built upon three elements: exact 
methods, test limits and selection of reference standard. Pharmacopeia monographs 
Figure 2. 
Requirements for chemical precursors used in preparation of radiopharmaceuticals depending on their 
regulatory status.
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comprise a set of critical attributes categorized into three subdivisions: identity, 
tests (related substances, residual solvents, metal catalyst or metal reagent residues, 
microbial contamination, bacterial endotoxin) and assay of the active substance. To 
ensure the appropriate quality, reference substances (like primary standards e.g. Ph. 
Eur. Chemical Reference Substance, CRS, or Pharmaceutical Secondary Standard, 
PSS) are used as a standard in an assay, identifications, or purity test. CRS or PSS are 
often characterized and evaluated for its intended purpose by additional procedures 
other than those used in routine testing [25].
For in-house prepared radiopharmaceuticals the confirmation of the chemical 
identity and purity of the precursor are the minimum quality control required, 
in order to qualify the material for subsequent clinical radiolabeling. Additional 
testing may apply if necessary for the specific process. For example, testing of 
trace metals content may not be necessary when the material will be subsequently 
radiolabeled with halogens, but is absolutely critical when the material is intended 
for labelling with radiometals [26].
To bring a novel radiopharmaceutical into the clinic it is needed that specific 
quality requirements for the radiopharmaceutical precursor are established, the 
range of testing would depend on their status and/or intended use. It is worth 
noting that for Phase I clinical trials full analytical validation is not necessary (only 
method suitability should be confirmed) [21]. While analytical methods used to 
evaluate a batch of API for clinical trials may not yet be validated, they should be 
scientifically sound [27].
There are some specific requirements for the large-sized molecules (e.g. proteins 
or monoclonal antibodies) as radiopharmaceutical precursors [28]. Monoclonal 
antibodies are immunoglobulins (Ig) with a defined specificity derived from a 
monoclonal cell line. Their biological activities are characterized by a specific 
binding characteristic to a target ligand (e.g. antigen) and they may be generated 
by recombinant DNA (rDNA) technology, hybridoma technology, B lymphocyte 
immortalization or other technologies. Generally, when chemical precursors are 
manufactured using substances of human or animal origin, the requirements of Ph. 
Eur. chapter 5.1.7. Viral safety [29] and the general monograph Products with risk of 
transmitting agents of animal spongiform encephalopathies (1483) [30] apply.
Stability testing is part of the chemical precursor’s characterization. Detailed 
requirements for carrying out stability studies are included in the ICH guideline 
Q1A (R2) [31]. The purpose of stability testing is to provide evidence on how the 
quality of a substance varies with time under the influence of a variety of environ-
mental factors such as temperature, humidity, and light, and to establish a re-test 
period and recommended storage conditions. Stability studies should be carried 
out on at least three batches and include testing parameters of the chemical precur-
sor that are susceptible to changes during storage and may affect quality, safety 
and efficacy (e.g. chemical purity and/or assay). The validated analytical methods 
should be used in these tests. For method validation, it is essential to investigate 
degradation products and establish degradation pathways under stress conditions 
(e.g. heat, humidity, light, acid/base hydrolysis and oxidation).
4. Peptides as precursors for radiopharmaceutical preparations
4.1 General consideration
Peptides are an emerging class of compounds that have application in 
 theranostics of several diseases, mainly in cancer [32–36]. These chemical pre-
cursors are positioned between the classic small organic molecules and the high 
Theranostics - An Old Concept in New Clothing
6
molecular weight biomolecules. The interest of the scientific community for peptide 
drugs has been continuously growing. Currently, more than 60 peptide-based 
pharmaceuticals are marketed, over 150 peptides are in active clinical trials and 
estimated 500 more are in preclinical stages of development [37, 38]. Chemically, 
peptides have poly-amino acids structure ranging from 3 to 100 amino acids 
(less than 10 kDa) linked by a peptide (amide, –CONH–) bond, and are lacking 
a tertiary structure. From the biological point of view, peptides are important 
regulators of growth and cellular functions in normal tissue and tumors. They can 
act as cytokines, chemokines, neurotransmitters, hormones and growth factors. 
Generally, they offer many advantages over other groups for radiopharmaceutical 
applications. Peptides demonstrate high receptor specificity and selectivity, as well 
as binding affinity, good tissue penetration and favorable pharmacokinetic profiles. 
Most of them is characterized by low toxicity and immunogenicity [39, 40]. Their 
compact size results in rapid targeting and blood clearance. As a consequence low 
nonspecific uptake in non-targeted tissues and high target-to-background ratios are 
achieved. Moreover, peptides can be easily chemically synthesized in high purity, 
modified and stabilized to obtain optimized pharmacokinetic parameters. These all 
attributes together with ability to attach different chelating agents, prosthetic group 
and availability of  various bioconjugation techniques make peptides an important 
target platform for theranostic radiopharmaceuticals [41, 42].
Peptide-based radiopharmaceuticals were introduced into the clinic more than 
three decades ago [43]. Since that time, several theranostic radioligand platforms 
are used for diagnosis and peptide receptor radionuclide therapy (PRRT) of dif-
ferent cancer types. In this concept, peptide analogs directed against somatostatin 
receptors (SSTR) play a crucial role [44]. The most prominent example of the 
theranostic pair of radiolabeled peptides are DOTA-conjugated SSTR agonist 
DOTA-(D-Phe1, Tyr3, Thr8)-octreotate (DOTA-TATE) labeled with 68Ga and 177Lu 
(Figure 3). The marketing authorization of NETSPOT® ([68Ga]Ga-DOTATATE) 
in 2016 and LUTATHERA® ([177Lu]Lu-DOTATATE) in early 2018 [45] encouraged 
the research in this field to develop improved radiolabeled peptides targeting other 
receptor/antigen families, exemplified by the prostate specific membrane antigen 
(PSMA) [46], gastrin-releasing peptide receptor (GRPr) [47] and cholecysto-
kinin-2 receptor (CCK2R) [48, 49]. Some of these peptides are currently under 
clinical investigation.
Figure 3. 
Structure of DOTA-TATE for labelling with theranostics pair of radionuclides: Gallium-68 (68Ga) and 
lutetium-177 (177Lu).
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4.2 Quality aspects
Peptides as precursors for radiopharmaceutical preparations, similarly to 
other chemical precursors, require adequate specification as a part of their quality 
assurance in order to demonstrate the safety and efficacy of the final radiopharma-
ceutical preparation. Currently, no individual pharmacopeia monograph of peptide 
used as radiopharmaceutical precursors is available. Thus, the quality specification 
should be established according to the general requirements [4, 50]. Herein, we pro-
vide an overview of recommended methods and test limits for the characterization 
of peptides. The set of analytical procedures that need to be considered is presented 
in Table 1. However, it should be noted that new analytical methods and modifica-
tions to existing ones are continuously being developed and should be utilized 
where appropriate.
Parameters Typical methods Typical acceptance criteria
Characters
- Appearance/color Visual inspection White or almost white powder
- Solubility Visual inspection Solubility in water, ethanol and dilute acid 
or alkali
Identification
- Active moiety RP-HPLC-UV Retention time versus reference
MS or Mass spectrum versus reference
NMR NMR spectrum versus reference
IR IR spectrum versus reference
AAA (GC) AA: theoretical content ±20%
Purity tests
- Related substances HPLC-UV Individual, unidentified: < 2.0%
Total: ≤ 3.0%
- Residual solvents (Headspace) GC Acetonitrile: ≤ 0.5%
- Residual metals AAS/ICP-AES/ICP-MS Pt, Pd, Ir, Rh, Ru, Os, Mo, Ni, Cr, V, Pb, Hg, 
Cd, Tl: ≤ 0.01%
- Residual reagents HPLC-UV/IC/GC Trifluoracetic acid: ≤ 1.0%*
Counter-ion content HPLC-UV/IC/GC Acetic acid: target ±5%
Trifluoracetic acid: target ±5%
Water content Karl-Fisher ≤ 10.0%
Assay (net peptide content) RP-HPLC-UV or CHN ≥ 75.0%
Bioburden TAMC plate count ≤ 103 CFU/g for bulk
≤ 102 CFU per container
TYMC plate count ≤ 102 CFU/g for bulk
≤ 101 CFU per container
Bacterial endotoxins Gel-clot ≤ 100 IU/g for bulk
≤ 10 IU per container
*The residual TFA content is determined when AcOH or HCl are used as counter-ions.
Table 1. 
Summary of the recommended quality parameters for peptides used as radiopharmaceutical precursors.
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4.2.1 Appearance
The preliminary quality evaluation of peptides is based on the visual inspection 
of the appearance/color and solubility. This parameter is given only for information, 
it is not a requirement in a strict sense. If any of the characteristics change during 
storage, this change should be investigated and appropriate action taken. A typical 
description of peptide appearance is: white to almost white, freeze-dried powder and 
solubility is stated in water, ethanol and dilute solutions of acids and alkali [38, 51].
4.2.2 Identification
According to the ICH Q6A guideline [25] identification testing should allow to 
discriminate between compounds of closely related structure which are likely to 
be present (e.g. peptides with altered sequences or functional groups that may be 
formed during the synthesis). The identification test should include combination of 
different procedures (mostly two) and should be specific and unequivocal. Several 
techniques are currently in use for confirmation of peptide identity: HPLC-UV, 
nuclear magnetic resonance spectrometry (NMR), mass spectrometry (MS), 
infrared absorption spectrophotometry (IR), amino acid analysis (AAA) or peptide 
sequencing [51]. The method of choice is typically HPLC-UV based on retention 
time by comparison with reference standard, since the separation by RP-HPLC 
is often utilized and the method is widely available. UV detection of peptides is 
realized at 210–220 nm and 250–290 nm for aromatic side chains of phenylalanine, 
tyrosine and tryptophan. Identification solely by a chromatographic retention 
time is not regarded as specific and should be complemented by spectrometric 
techniques. The NMR spectroscopy is the method that allows to unequivocally 
define the structure of a peptide in the terms of amino acid composition, sequence 
and chirality. Identification by NMR spectrometry is usually limited to peptides 
comprising up to 15 amino acids and requires complex data interpretation. For this 
reason NMR technique is primarily replaced by mass spectroscopy (MS). This tech-
nique provides highly accurate molecular weight information on intact molecules, 
which is an advantage of MS for peptide identification. The peptide molecular mass 
is most commonly determined by using the electrospray ionization method (ESI), 
which occurs through the addition or removal of protons and appears as singly or 
doubly charged ions. As alternative for the more sophisticated spectroscopic meth-
ods, amino acid analysis (AAA) could be considered. This technique involves the 
hydrolysis of the peptide (usually in acidic conditions) to its individual amino acid 
residues, followed by chromatographic separation and detection/quantification. 
The method also enables the determination of the enantiomeric purity with the use 
of appropriate reference standards. However, this method may not be applicable to 
peptides containing unnatural amino acids and/or specific chelators. The NMR and 
AAA as well as peptide sequencing techniques are generally used for characteriza-
tion of PSS.
In the two recently published papers the identity of DOTA-TATE has been 
confirmed using suitable instrumental techniques; Sikora et al. [52] confirmed the 
identity of DOTA-TATE using three different methods: MS, IR and HPLC. Similarly, 
in the work by Raheem at al [53] the final product was analyzed using high resolu-
tion mass spectrometry for identification and analytical HPLC for purification; it 
was detected via analytical HPLC at a retention time of 9.52 min and detected by 
HRMS-ESI (calc m/z for [(DOTA-TATE +2H)/2]+: 718.3028, found: 718.3046 with 
−0.1144 ppm error).
In our experience ESI-MS in positive ionization mode was used to confirmed 
whether the masses of ions at m/z 1435.6 ± 1.0 [M + H]+ and 718.3 ± 1.0 [M + 2H]2+ 
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correspond to the monoisotopic mass of peptide [M] as presented in Figure 4. 
DOTA-TATE PSS was used as reference in IR analysis. Also a gradient HPLC-UV 
(220 nm) served as identity test of DOTA-TATE by comparison with the reference 
standard (Rt ± 5.0%). The same HPLC method was used for determination of 
peptide purity and assay. The representative HPLC chromatograms of DOTA-TATE 
and DOTA-TATE PSS are given in Figure 5.
4.2.3 Related substances
Peptides are usually chemically synthesized using solid-phase peptide synthesis 
(SPPS) [54]. In this multi-stage process, amino acids are linked to each other during 
individual coupling steps, thus constructing the desired peptide sequence. This 
occurs when the carboxylic end of the sequence is covalently attached to a solid sup-
port matrix. The complexity of the peptide production process results in a greater 
diversity of potential impurities. Heterogenicity of the impurity profile is observed 
Figure 4. 
ESI-MS spectrum for DOTA-TATE.
Figure 5. 
HPLC-UV (220 nm) chromatograms of (I) DOTA-TATE Rt = 19.831 min and (II) DOTA-TATE PSS 
Rt = 19,936 min. HPLC method: Luna C18(2) column; Mobile phase - A: water with 0.1% TFA, B: Acetonitrile 
with 0.1% TFA; gradient profile – From 0 to 25 min: 0–50% B; flow - 0.8 mL/min, oven temperature - 30°C.
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even among peptides manufactured by the same synthetic route. The impurities 
can originate from raw materials, the manufacturing process, degradation or may 
be formed during storage. Although protecting groups, scavengers or activated 
functional groups are used to prevent undesired side-chain reactions the peptide 
manufacturing process leads to formation of closely related impurities. The most 
common impurities are products of racemization, deamidation, amino acid dele-
tion or insertion, acetylation, oxidation, β-elimination, cyclization, reduction and 
incomplete deprotection [51]. The presence of related peptide impurities is typi-
cally determined using gradient reversed-phase HPLC method with UV detection, 
because of its selectivity, high sensitivity, low limit of detection, quantification 
and robustness. The developed HPLC method should allow sufficient separation of 
potential impurities from manufacturing process as well as degradation products. 
The acceptance criteria for related substances according to the Ph. Eur. General 
Monograph 2902 [4] are presented in Table 2.
Specific thresholds should be applied for impurities known to be unusually 
potent or to produce toxic or unacceptable pharmacological effects.
4.2.4 Metallic impurities
The presence of inorganic impurity should also be considered, in particular 
when radiolabeling of the peptide with radiometals is concerned. According to the 
Ph. Eur. general monograph (2902), the metal residues in peptides should be deter-
mined if the manufacturing process is known or suspected to lead to its presence, 
e.g. due to the use of specific metal catalyst (e.g. Pd) or metal containing reagents. 
The content for each of the following metals: Pt, Pd, Ir, Rh, Ru, Os, Mo, Ni, Cr, V, 
Pb, Hg, Cd, Tl in the peptide precursors are limited to 0.01%. The metal impurities 
are typically examined using atomic absorption spectrometry (AAS), inductively 
coupled plasma with atomic emission spectrometry detection (ICP-AES) or mass 
spectrometry detection (ICP-MS) techniques. Determination of residual metals in 
peptides can be crucial for precursors intended for radiometal labeling [55]. It has 
been proven that the presence of certain metals can significantly affect the labeling 
efficiency through competitive chelation.
4.2.5 Residual solvents
In addition to related substances the residual solvents are required to be exam-
ined as impurities in peptide precursors. Residual solvents in pharmaceuticals are 
defined as organic volatile chemicals that are used in the manufacturing process. 
The solvents are not completely removed by practical manufacturing techniques 
(e.g. lyophilization process). General guidelines established by the ICH divide 
solvents into three classes [56]. The Class 1 solvents should not be used in the final 
step of the manufacturing process of chemical precursors, because of toxicity and 
environmental impact. The use of the Class 2 solvents should be limited due to 
potential toxicity and Class 3 solvents are regarded as posing a lower risk to human 
Reporting threshold 0.2 per cent
Identification threshold 2.0 per cent
Total unspecified impurities Maximum 3.0 per cent
Table 2. 
Acceptance criteria for related substances [4].
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health. Based on the permitted daily exposure (PDE), Class 2 and 3 solvents are 
limited to 0.5%. Residual solvents are typically determined using chromatographic 
techniques such as gas chromatography (GC) coupled with static headspace sam-
pling. Many solvents are usually used in the peptides synthetic process. However, as 
the advantage of the SPPS and lyophilization process, the most frequently detected 
solvent is only acetonitrile (Class 2 solvent), used as the component of the mobile 
phase in the final purification process by preparative HPLC.
4.2.6 Counter-ion content
Synthetic peptides usually contain counter-ions on protonated amino func-
tional groups (N-terminus, Arg, His, Lys, etc.). The presence of counter-ions such 
as acetate, chloride or trifluoroacetate results from the peptide post synthetic 
cleavage and/or purification process. Depending on the peptide sequence they 
reduce the net peptide content by 5 to 25%, but are not considered as impurity. 
Radiopharmaceutical preparations for diagnostic or therapeutic purposes are based 
on the net peptide content and thus the amount of residual counter-ions needs to 
be assessed. To determine counter-ion amounts different method are being used 
such as: GC, HPLC-UV or ion chromatography (IC). Trifluoroacetic acid (TFA) 
determined by IC at the level of ca. 20% in DOTA-TATE [52], corresponded to 
three TFA molecules associated to single peptide molecule. TFA is commonly used 
as a chemical reagent to remove residual protecting groups during purification of 
peptides and also as a mobile-phase modifier in a reversed-phase chromatography. 
Therefore, when the counter-ion finally is AcOH or HCl, determination of the TFA 
residual content is mandatory.
4.2.7 Water content
In order demonstrate a lot-to-lot consistency the test for water content (residual 
moisture remaining from the lyophilization process) should be also performed. This 
parameter may affect the stability of the peptide. For residual water Karl-Fischer 
titration method as well as GC method with thermal conductivity detector (TCD) 
[57] are commonly used and water content is limited to max. 10%.
4.2.8 Assay
Generally, assay is defined as a net peptide content. The lyophilized peptide 
contains also water, counter ions and residual solvents. The net peptide content is 
referred to percentage of peptide material in the lyophilized peptide. According to 
ICH guideline Q6A, a specific stability-indicating procedure should be included in 
the specifications to determine the content of the drug substance. There are two 
main approaches to determine net peptide content. The first method is a relative 
assay against a well-defined chemical reference substance, performed using com-
parative chromatographic procedures. Usually the same RP-HPLC method is used 
for both assay, identification and related substances. The second approach is an 
absolute assays involving a functional group (e.g. AAA or titration methods) or a 
nitrogen content analysis. The nitrogen content is determined from the results of 
elemental analysis CHN. The calculation of the net peptide content is based on the 
relation between determined %N to the theoretical content in the peptide structure. 
For example, this method was used to DOTA-TATE assay determination. Peptide 
content calculated from elemental analysis was ca. 78.0%, which was in agreement 
with the generally accepted limit ≥75% [52].
Theranostics - An Old Concept in New Clothing
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4.2.9 Microbiological assays
The presence of microorganisms may affect the stability of drug substances due 
to their propensity to degrade/metabolize peptides. Microbiological examinations 
involve the bioburden control (Ph. Eur 2.6.12) and content of bacterial endotoxins 
(Ph Eur. 2.6.14). The microbial enumeration tests for total aerobic microbial counts 
(TAMC) and total yeast and mold counts (TYMC) must adhere to the acceptance 
criteria of 103 CFU/g and 102 CFU/g for bulk material and 102 CFU/g and 101 CFU 
per container for chemical precursors packed in single and multi-dose containers, 
respectively. Bacterial endotoxin can be determined by the gel-clot or photometric 
methods (turbidimetric and chromogenic techniques) and acceptance criteria are 
limited to a maximum 100 IU/g for bulk material or maximum 10 IU per container 
for chemical precursors packed in single-dose and multidose containers.
5. Radionuclide precursors
Radionuclide precursors are offered as solutions for radiolabeling with MA, they 
are also locally produced for the in-house preparation of radiopharmaceuticals. 
There is an ongoing debate whether radionuclide precursors always have to be 
considered as medicinal product, or also can be provided as a starting material [58]. 
Unlike for chemical precursors for radiopharmaceutical preparation, up to date 
there is no monograph in the Ph. Eur. that sets out general requirements for radio-
nuclide precursors. This is due to the fact that the quality requirements for radionu-
clides used to obtain diagnostic and therapeutic preparations are highly varying and 
depend on the irradiation route and chemical processing involved, which mainly 
affect the parameters of radionuclide purity or specific activity.
However, there are several individual Ph. Eur. monographs for radionuclide 
precursors. Two of these concern radionuclide precursors used to prepare radiophar-
maceuticals for therapeutic use. These are: Lutetium (177Lu) solution for radiolabelling 
(mon. 2798) [59] and Yttrium (90Y) chloride solution for radiolabelling (mon. 2803) 
[60]. There are also six monographs published for radionuclide precursors for prepa-
ration of diagnostic radiopharmaceuticals: Fluoride (18F) solution for radiolabelling 
(mon. 2390) [61], Sodium iodide (123I) solution for radiolabelling (mon. 2314) [62], 
Sodium iodide (131I) solution for radiolabelling (mon. 2121) [63], Indium (111In) 
chloride solution (mon. 1227) [64] and Gallium (68Ga) chloride solution for radio-
labelling (mon. 2464) [65] and a newly published monograph for Gallium (68Ga) 
chloride (accelerator-produced) solution for radiolabelling (mon. 3109) [66].
Focusing attention on theranostic radiopharmaceuticals, herein the quality 
requirements only for metallic radionuclide precursors used in diagnostics and 
therapy are compared. Table 3 shows the exemplary quality requirements for radio-
nuclide precursor for therapeutic use (177Lu) and a matching radionuclide precursor 
for diagnostic use (68Ga).
Comparing the requirements of these two monographs there are apparently 
large differences in numerical values seen, especially for metal ion content and 
radiochemical purity. However, when the radioactivity of these radionuclides 
( different for therapeutic or diagnostic use) is considered, there are basically no 
differences in quality requirements for both radionuclides. This can be demon-
strated on the example of the DOTA-TATE preparations with 177Lu and 68Ga. For 
therapy 7.4 GBq of [177Lu]Lu-DOTA-TATE is used and this preparation contains 
ca. 0.2 mg of DOTA-TATE. Typical dose of [68Ga]Ga-DOTA-TATE is 200 MBq and 
the ligand content in the preparation should not exceed 0.05 mg. Therefore, when 
analyzing the limit of metallic impurities, e.g. Zn in the radionuclide precursor, 
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similar values are obtained in both cases, i.e. maximum 37 ng and 40 ng per micro-
gram of DOTA-TATE for lutetium-177 and gallium-68, respectively.
When the radiochemical purity is compared, the higher limit of permissible 
other forms of diagnostic radionuclide ([68Ga]gallium(III) ion: minimum 95%) 
than for the therapeutic radionuclide ([177Lu]Lutetium(III) ion: minimum 99%) 
does not result in a higher risk to the patient. Thus, 5% of other forms of a trivalent 
gallium-68 ion may result in the deposit of 10 MBq of this radionuclide in undesir-
able chemical form in non-target organs, while for 1% lutetium-177 it is as much as 
74 MBq of uncontrolled chemical form. However, it must be noted that a stricter 
limit for the latter radionuclide is difficult to achieve due to the limitations of the 
analytical methods, which are characterized by an approximate 1% uncertainty of 
determination.
Lutetium (177Lu) solution for radiolabelling
(Ph. Eur. 2798 [59])
Gallium (68Ga) chloride solution for 
radiolabelling
(Ph. Eur. 2464 [60])
pH: 1.0 to 2.0, using a pH indicator strip R. pH: maximum 2, using a pH indicator strip R.
Lutetium: Inductively coupled plasma-atomic emission 













- the total radioactivity due to ytterbium-175 (impurity 
B) is not more than 0.1 per cent;
– the total radioactivity due to lutetium-177 m (impurity 
A) is not more than 0.07 per cent;
– the total radioactivity due to radionuclidic impurities 
other than A and B is not more than 0.01 per cent.
RADIONUCLIDIC PURITY
Gallium-68: minimum 99.9 per cent of the total 
radioactivity.
A. Gamma-ray spectrometry.
Limit: peaks in the gamma-ray spectrum 
corresponding to photons with an energy 
different from 0.511 MeV, 1.077 MeV, 
1.022 MeV and 1.883 MeV represent not more 
than 0.1 per cent of the total radioactivity.
B. Germanium-68 and gamma-ray-emitting 
impurities. Gamma-ray spectrometry.
Result: the total radioactivity due to 
germanium-68 and gamma-ray-emitting 
impurities is not more than 0.001 per cent.
RADIOCHEMICAL PURITY
[177Lu]lutetium(III) ion: minimum 99 per cent of the total 
radioactivity due to lutetium-177.
RADIOCHEMICAL PURITY
[68Ga]gallium(III) ion: minimum 95 per cent of 
the total radioactivity due to gallium-68.
Bacterial endotoxins (2.6.14): less than 175 IU/V, V being 
the maximum volume to be used for the preparation of a 
single patient dose, if intended for use in the manufacture 
of parenteral preparations without a further appropriate 
procedure for the removal of bacterial endotoxins.
Bacterial endotoxins (2.6.14): less than 175 IU/V, 
V being the maximum volume to be used 
for the preparation of a single patient dose, 
if intended for use in the manufacture of 
parenteral preparations without a further 
appropriate procedure for the removal of 
bacterial endotoxins.
Sterility: If intended for use in the manufacture of 
parenteral preparations without a further appropriate 
sterilization procedure, it complies with the test for 
sterility prescribed in the mon. 0125. The preparation 
may be released for use before completion of the test.
Table 3. 
Comparison of Ph. Eur. requirements for selected radionuclide precursors.
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Bearing in mind that the differences in the profile of radionuclide contamina-
tion depend on the radionuclide production process [67], it is unlikely that uniform 
quality requirements for radionuclide precursors will be set in numerical terms. 
Each radionuclide precursor should be evaluated on a case-by-case basis, taking 
into account the physical characteristics of the radionuclide, its mode of irradiation 
and chemical processing as well as the envisaged clinical use and the dose planned 
for administration to the patient. This is clearly reflected in monographs referred in 
this Chapter. The monograph for 177Lu [59] applies to both the direct and indirect 
production routes of 177Lu in nuclear reactors and covers all quality aspects regard-
less the different specific radioactivity and impurity profiles. The decision is left to 
the producer of the final radiopharmaceutical preparation to use the appropriate 
solution for radiolabeling. However, the relevant information needs to be stated 
on the label. This is different in case of 68Ga, there are two different monographs 
specifying its quality requirements depending whether it’s generator [65] or accel-
erator produced [66]. One can expect that a similar individual approach applies to 
the future monographs for new theranostic radionuclides, for example 47Sc, which 
can be either accelerator or reactor produced [68].
6. Conclusion
Are the requirements for radiopharmaceutical precursors overregulated? With 
the development of new theranostic procedures involving radiopharmaceuticals, 
there is a need for proper qualitative evaluation of the final radiopharmaceutical 
preparation and both of the radiopharmaceutical precursors to ensure efficacy and 
safety of the treatment. An excellent example of the long pathway of a radiophar-
maceutical, 111In-CP04, a peptide targeting the cholecystokinin-2 receptor, from the 
preclinical development over establishing the required pharmaceutical documenta-
tion to designing and submitting a clinical trial in patients with Medullary Thyroid 
Carcinoma, was recently presented [16]. All the quality aspects of CP04 as chemical 
precursor have been addressed in the IMPD in view of the quality and suitability of 
the radiolabeled preparation, 111In-CP04, in order to bring it to the clinic.
In this Chapter, the quality requirements applicable to radiopharmaceutical 
precursors in the context of their regulatory status in Europe were reviewed. EMA 
and Ph. Eur. provide public standards for manufacture and quality control of these 
precursors by establishing specifications and acceptance criteria. While in the 
case of radiopharmaceuticals with MA and CT regulations quite strictly define the 
quality and documentation requirements, such standards for in-house produced 
radiopharmaceuticals are still awaited.
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